HUMORAL AND CELLULAR IMMUNE PARAMETERS IN UNTREATED AND PHENYTOIN-TREATED OR CARBAMAZEPINE-TREATED EPILEPTIC PATIENTS

被引:52
作者
BASARAN, N
HINCAL, F
KANSU, E
CIGER, A
机构
[1] UNIV HACETTEPE, FAC PHARM, DEPT TOXICOL, ANKARA 06100, TURKEY
[2] UNIV HACETTEPE, FAC MED, INST ONCOL, ANKARA 06100, TURKEY
[3] UNIV HACETTEPE, FAC MED, DEPT NEUROL, ANKARA 06100, TURKEY
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1994年 / 16卷 / 12期
关键词
D O I
10.1016/0192-0561(94)90087-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The peripheral blood lymphocyte subsets, serum immunoglobulins (Ig A, G, M), and C3 and C4 complement protein concentrations were determined in 40 healthy subjects, 30 phenytoin-treated, 22 carbamazepine-treated and 38 untreated epileptic patients. The levels of B-lymphocytes, IgM and C3 complement proteins were found to be significantly higher in untreated epileptics than in healthy controls (P<0.01, P<0.02 and P<0.05, respectively). The absolute number of B-lymphocytes appeared to be unaffected by phenytoin or carbamazepine treatment; however, IgM levels were significantly lower in carbamazepine-treated patients than both epileptic (P<0.01) and healthy (P<0.05) controls. Phenytoin-treated patients had a significant reduction in the mean IgA and IgG levels compared to healthy and epileptic controls (P<0.05). With both drug treatments, significantly lower T-suppressor lymphocyte counts and thus higher T-helper to T-suppressor lymphocyte ratios were observed with respect to healthy and epileptic controls. Our results demonstrate that while phenytoin decreases serum IgA and IgG levels, carbamazepine reduces IgM levels significantly, and untreated epileptics show immune profiles significantly different to those of healthy subjects, suggesting that epilepsy per se may be associated with certain immune aberrations induced by antiepileptic drugs.
引用
收藏
页码:1071 / 1077
页数:7
相关论文
共 36 条
  • [1] IMMUNOLOGICAL ASPECTS OF EPILEPSY
    AARLI, JA
    [J]. BRAIN & DEVELOPMENT, 1993, 15 (01) : 41 - 50
  • [2] DRUG-INDUCED IGA DEFICIENCY IN EPILEPTIC PATIENTS
    AARLI, JA
    [J]. ARCHIVES OF NEUROLOGY, 1976, 33 (04) : 296 - 299
  • [3] IMMUNOLOGICAL ASPECTS OF EPILEPSY
    AARLI, JA
    FONTANA, A
    [J]. EPILEPSIA, 1980, 21 (05) : 451 - 457
  • [4] CHANGES IN SERUM IMMUNOGLOBULIN LEVELS DURING PHENYTOIN TREATMENT OF EPILEPSY
    AARLI, JA
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1976, 54 (05): : 423 - 430
  • [5] ANDERMANN E, 1982, GENETIC BASIS EPILEP, P355
  • [6] ANDERMANN E, 1985, GENETIC ASPECTS HUMA
  • [7] ANDERSEN P, 1977, ACTA MED SCAND, V201, P69
  • [8] EFFECTS OF PHENYTOIN ON MANS IMMUNITY - EVALUATION OF CHANGES IN SERUM IMMUNOGLOBULINS, COMPLEMENT, AND ANTI-NUCLEAR ANTIBODY
    BARDANA, EJ
    GABOUREL, JD
    DAVIES, GH
    CRAIG, S
    [J]. AMERICAN JOURNAL OF MEDICINE, 1983, 74 (02) : 289 - 296
  • [9] SERUM IMMUNOGLOBULINS, COMPLEMENT LEVELS AND LYMPHOCYTE SUBPOPULATIONS IN PHENYTOIN-TREATED EPILEPTIC PATIENTS
    BASARAN, N
    KANSU, E
    HINCAL, F
    [J]. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1989, 11 (2-3) : 335 - 346
  • [10] IMMUNOGLOBULINS IN EPILEPSY
    BASSANINI, M
    BAEZ, A
    SOTELO, J
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1982, 56 (2-3) : 275 - 281